Skip to content

FastForward Innovations Shares Fall After Agreeing To Sell Interest In EMMAC

Practice Stock Trading Your capital is at risk
Updated 22 Jul 2021

Shares of FastForward Innovations (LON: FFWD) are down on Wednesday after the company said it has agreed to sell its entire interest in EMMAC Life Sciences as part of Curaleaf's takeover of the company.


EMMAC, a cannabis firm, will be acquired by Curaleaf, a US provider of consumer cannabis products, for a base consideration of approximately $285 million.

FastForward has agreed to sell its stake in the company, 6.7 million shares and a £750,000 convertible loan note, for £5.04 million.

Due to regulatory conditions surrounding Curaleaf's involvement in the recreational cannabis market in North America, AIM-listed FastForward is unable to participate in the Curaleaf transaction and so will sell the shares and loan note to an unrelated party.

FastForward expects to record a profit on the Sale of approximately £1,931,459 and intends to use the proceeds for making further investments, following its investing policy.

“This is an extremely positive outcome for FastForward and we are delighted to have made a significant return on our original investment in EMMAC, further increasing our confidence in our investment strategy and our ability to deliver financial gains, particularly in the medical cannabis, cannabinoid wellness and life sciences sectors,” commented Ian Burns, Chairman of FastForward Innovations.

Despite initially rising following the news, FastForward Innovations share price is now down 10.56% at 9.60p.

Should you invest in FastForward Innovations shares? FastForward Innovations shares are traded on the AIM market of the London stock exchange (the alternative investment market) which is the sub market specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are FastForward Innovations shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies